Last reviewed · How we verify
IGM2323
At a glance
| Generic name | IGM2323 |
|---|---|
| Sponsor | IGM Biosciences, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma (PHASE1, PHASE2)
- Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IGM2323 CI brief — competitive landscape report
- IGM2323 updates RSS · CI watch RSS
- IGM Biosciences, Inc. portfolio CI